Advisory Associates Advise Cytorex BioSciences in Seed Round Financing


Advisory Associates and PharmaBioSource Advise Cytorex Biosciences in its $40 Million Seed Round Financing
McLean, VA — Advisory Associates, Inc. andPharmaBioSource, Inc. have been retained as exclusive advisors to Cytorex Biosciences, Inc., a pre-clinical stage biopharmaceutical company, in connection with obtaining $40 million in financing.
Cytorex Biosciences will use the funds to complete development of its leading therapeutic candidate,Cytoreg®, through Phase II trials for the indication of malignant brain tumors (Glioblastoma Multiforme).
About Cytorex Biosciences, Inc.
Cytorex Biosciences develops therapeutic candidates primarily for treatment of cancer,as well as discovery and development for indications of diseases of immunological origin. Their lead drug candidate, Cytoreg®, is currently in preclinical testing forcancer, as well as in discovery and preclinical development for indications in diseases of immunological origin. For more information about Cytorex Biosciences, Inc servicesand transactions, visit